Chondroitin sulfate A regulates fibrosarcoma cell adhesion motility and migration through JNK and tyrosine kinase signaling pathways

In Vivo

Volumn 23, Issue 1, 2009, Pages 69-76

  Fthenou, Eleni ^a   Zong, Fang ^b   Zafiropoulos, Alexandros ^a   Dobra, Katalin ^b   Hjerpe, Anders ^b   Tzanakakis, George N ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chondroitin sulfate A; JNK; Migration; PTK

Indexed keywords

ADENINE XYLOSIDE; CHONDROITIN 4 SULFATE; CHONDROITIN SULFATE; GLYCOSAMINOGLYCAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N ACETYLGALACTOSAMINE 4 SULFATASE; PROTEIN TYROSINE KINASE; PROTEOCHONDROITIN SULFATE; PROTEOGLYCAN; SODIUM CHLORATE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CARBOHYDRATE SYNTHESIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CONTROLLED STUDY; FIBROSARCOMA; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOTAXIS; CHONDROITIN SULFATES; FIBROSARCOMA; HUMANS; MAP KINASE KINASE 4; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 63049112729     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Webb DJ, Parsons JT and Horwitz AF: Adhesion assembly, disassembly and turnover in migrating cells over and over and over again. Nat Cell Biol 4: E97-100, 2002.
2. Huang C, Jacobson K and Schaller MD: MAP kinases and cell migration. J Cell Sci 117: 4619-4628, 2004.
3. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002.
4. Mark MP, Baker JR, Kimata K and Ruch JV: Regulated changes in chondroitin sulfation during embryogenesis: an immunohisto-chemical approach. Int J Dev Biol 34: 191-204, 1990.
5. Bower L, Braven J and Manley G: The isolation and characterization of glycosaminoglycans in normal human serum. J Pharm Biomed Anal 6: 67-74, 1988.
6. Juvani M, Friman C, Ranta H and Wegelius O: Isolation and characterization of undersulphated chondroitin-4-sulphate from normal human plasma. Biochim Biophys Acta 411: 1-10, 1975.
7. Staprans I and Felts JM: Isolation and characterization of glycosaminoglycans in human plasma. J Clin Inv 76: 1984-1991, 1985.
8. Piepkorn M, Hovingh P and Linker A: Evidence for independent metabolism and cell surface localization of cell surface localization of cellular proteoglycans and glycosaminoglycan free chains. J Cell Physiol 135: 189-199, 1988.
9. Garrigues HJ, Lark MW, Lara S, Hellstrom I, Hellstrom KE and Wight TN: The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface. J Cell Biol 103: 1699-1710, 1986.
10. Henke CA, Roongta U, Mickelson DJ, Knutson JR and McCarthy JB: CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J Clin Inv 97: 2541-2552, 1996.
11. Iida J, Skubitz AP, Furcht LT, Wayner EA and McCarthy JB: Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J Cell Biol 118: 431-444, 1992.
12. Li H, Leung TC, Hoffman S, Balsamo J and Lilien J: Coordinate regulation of cadherin and integrin function by the chondroitin sulfate proteoglycan neurocan. J Cell Biol 149: 1275-1288, 2000.
13. Denholm EM, Cauchon E, Poulin C and Silver PJ: Inhibition of human dermal fibroblast proliferation by removal of dermatan sulfate. Eur J Pharmacol 400: 145-153, 2000.
14. Denholm EM, Lin YQ and Silver PJ: Antitumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion. Eur J Pharmacol 416: 213-221, 2001.
15. Iida J, Meijne AM, Knutson JR, Furcht LT and McCarthy JB: Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol 7: 155-162, 1996.
16. Fthenou E, Zafiropoulos A, Tsatsakis A, Stathopoulos A, Karamanos NK and Tzanakakis GN: Chondroitin sulfate A chains enhance platelet-derived growth factor-mediated signalling in fibrosarcoma cells. Int J Biochem Cell Biol 38: 2141-2150, 2006.
17. Fthenou E, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos NK and Tzanakakis GN: Chondroitin sulfate prevents platelet-derived growth factor-mediated phosphorylation of PDGF-Rbeta in normal human fibroblasts severely impairing mitogenic responses. J Cell Biochem 103: 1866-76, 2008
18. Thurzo V, Popovic M, Matoska J, Blasko M, Grofova M, Lizonova A and Steno M: Human neoplastic cells in tissue culture: two established cell lines derived from giant cell tumor and fibrosarcoma. Neoplasma 23: 577-587, 1976.
19. Yip GW, Ferretti P and Copp AJ: Heparan sulphate proteoglycans and spinal neurulation in the mouse embryo. Development 129: 2109-2119, 2002.
20. Schwartz NB: Regulation of chondroitin sulfate synthesis. Effect of beta-xylosides on synthesis of chondroitin sulfate proteoglycan, chondroitin sulfate chains, and core protein. J Biol Chem 252: 6316-6321, 1977.
21. Nikitovic D, Zafiropoulos A, Tzanakakis GN, Karamanos NK and Tsatsakis AM: Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions. Anticancer Res 25: 2851-2856, 2005.
22. Syrokou A, Tzanakakis G, Tsegenidis T, Hjerpe A and Karamanos NK: Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure-function relationship. Cell Prolif 32: 85-99, 1999.
23. Baici A, Horler D, Moser B, Hofer HO, Fehr K and Wagenhauser FJ: Analysis of glycosaminoglycans in human serum after oral administration of chondroitin sulfate. Rheumatol Int 12: 81-88, 1992.
24. Akiyama T, Ishida J, Nakagawa S, Ogawara, H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262: 5592-5595, 1987.
25. Sarkar FH and Li Y: Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev 21: 265-280, 2002.
26. Berrier AL and Yamada KM: Cell-matrix adhesion. J Cell Physiol 213: 565-573, 2007.
27. Cox BD, Natarajan M, Stettner MR and Gladson CL: New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 99: 35-52, 2006.
28. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA and McCarthy JB: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 165: 881-891, 2004.
29. Moyano JV, Maqueda A, Albar JP and Garcia-Pardo A: A synthetic peptide from the heparin-binding domain III (repeats III4-5) of fibronectin promotes stress-fibre and focal-adhesion formation in melanoma cells. Biochem J 371: 565-71, 2003.
30. Iida J, Meijne AM, Oegema TR Jr, Yednock TA, Kovach NL, Furcht LT and McCarthy JB: A role of chondroitin sulfate glycosaminoglycan binding site in alpha4betal integrin-mediated melanoma cell adhesion. J Biol Chern 273: 5955-5962, 1998.
31. Karram K, Chatterjee N and Trotter J: NG2-expressing cells in the nervous system: role of the proteoglycan in migration and glial-neuron interaction. J Anat 207: 735-744, 2005.
32. Sneath RJ and Mangham DC: The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51: 191-200, 1998.
33. Yang J, Price MA, Neudauer CL,Wilson C, Ferrone S, Xia H, Iida J, Simpson MA and McCarthy JB: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol 165: 881-891, 2004.
34. Zou XH, Foong WC, Cao T, Bay BH, Ouyang HW and Yip GW: Chondroitin sulfate in palatal wound healing. J Dent Res 83: 880-885, 2004.
35. Volpi N, Bolognani L, Conte A and Petrini M: Effects of chondroitin sulfates with different structures on leukemia cells: U-937 cell proliferation and differentiation. Leuk Res 17: 789-798, 1993.
36. Moissoglu K and Schwartz MA: Integrin signalling in directed cell migration. Biol Cell 98: 547-555, 2006.
37. Almeida EA, Ilic D, Han Q, Hauck CR, Jin F, Kawakatsu H, Schlaepfer DD and Damsky CH: Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase. J Cell Biol 149: 741-754, 2000.
38. Katz BZ, Zohar M, Teramoto H, Matsumoto K, Gutkind JS, Lin DC, Lin S and Yamada KM: Tensin can induce JNK and p38 activation. Biochem Biophys Res Commun 272: 717-720, 2000.
39. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT and Horwitz AR: Cell migration: integrating signals from front to back. Science 302: 1704-1709, 2003.
40. Yujiri T, Nawata R, Takahashi T, Sato Y, Tanizawa Y, Kitamura T and Oka Y: MEK kinase 1 interacts with focal adhesion kinase and regulates insulin receptor substrate-1 expression. J Biol Chem 278: 3846-3851, 2003.
41. Huang C, Jacobson K and Schaller MD: A role for JNK-paxillin signaling in cell migration. Cell Cycle 3: 4-6, 2004.
42. Hehlgans S, Haase M and Cordes N: Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775: 163-180, 2007.
43. Hunter T: A thousand and one protein kinases. Cell 50: 823-829, 1987.
44. Ihn H and Tamaki K: Mitogenic activity of dermatofibrosarcoma protuberans is mediated via an extracellular signal related kinase dependent pathway. J Invest Dermatol 119: 954-960, 2002.
45. Yan C and Han R: Effects of genistein on invasion and matrix metalloproteinase activities of HT1080 human fibrosarcoma cells. Chin Med Sci J 14: 129-133, 1999.